Ascendis Pharma A (ASND) Operating Leases (2018 - 2023)

Ascendis Pharma A has disclosed Operating Leases across 6 years of filings, most recently posting $91.0 million for Q4 2023.

• Operating Leases for Q4 2023 came in at $91.0 million, down 6.48% year-over-year; the trailing twelve-month figure through Dec 2023 was $91.0 million (down 6.48% YoY), and the FY2023 annual result was $91.0 million, down 6.48% from the prior year.
• Operating Leases came in at $91.0 million for Q4 2023 at Ascendis Pharma A, down from $97.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $112.1 million in Q4 2021 to a low of $40.5 million in Q4 2019.
• The 5-year median for Operating Leases is $97.3 million (2022), against an average of $88.5 million.
• Across the five-year window, Operating Leases jumped 150.37% in 2020 and dropped 13.15% in 2022, its largest moves.
• Ascendis Pharma A's Operating Leases stood at $40.5 million in 2019, then jumped by 150.37% to $101.5 million in 2020, then rose by 10.43% to $112.1 million in 2021, then retreated by 13.15% to $97.3 million in 2022, then dropped by 6.48% to $91.0 million in 2023.
• The last three Operating Leases figures came in at $91.0 million (Q4 2023), $97.3 million (Q4 2022), and $112.1 million (Q4 2021), per Business Quant data.